Compared to older drugs for Parkinson disease, a newer class of medications called dopamine agonists might be better at preventing some of the disabling muscle control problems associated with the disease and its treatment, a new review concludes. However, patients who take the new drugs suffer from an increase in numerous side effects, and are more likely to drop out of treatment.